EXACT SCIENCES CORP: New Data Presented at SABCS 2021 Streng

- Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy MADISON

Related Keywords

Canada , United States , San Antonio , Texas , America , Kevin Kalinsky , Rick Baehner , Federico Maiardi , Stephanie Spanos , Megan Jones , Sciences Corp , Sciences On Facebook , National Cancer Institute , Precision Oncology At Exact Sciences , Sciences On Twitter Exactsciences , Nasdaq , Exchange Commission , Prnewswire Exact Sciences Corp , Genomic Health Inc , Cancer Research Network , Sciences Corporation , Antonio Breast Cancer Symposium , Recurrence Score , Research Network , Precision Oncology , New England Journal , Princess Margaret Trial , Exact Sciences , Poster Sessions , Spotlight Poster Discussions , North East England , Using Oncotype , Cancer Tissue , Genomic Health , Risk Factors , Annual Report , Quarterly Reports , Latin America , Oral Presentation , San Antonio Breast Cancer Symposium , Breast Can Res Treat , Ann Surg , Exact , Ciences , Orp , Data , Resented , Abcs , 021 , Trengthen , Value , Oncotype , Breast , Recurrence , Core , Pest , Enform , Linical , Decision , Baking ,